Short Interest in GeoVax Labs, Inc. (NASDAQ:GOVX) Grows By 240.4%

GeoVax Labs, Inc. (NASDAQ:GOVX) was the target of a large growth in short interest in the month of August. As of August 15th, there was short interest totalling 623,300 shares, a growth of 240.4% from the July 31st total of 183,100 shares. Approximately 11.9% of the shares of the company are sold short. Based on an average trading volume of 6,760,000 shares, the short-interest ratio is presently 0.1 days.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Noble Financial raised their target price on GeoVax Labs from $6.00 to $10.00 and gave the stock an “outperform” rating in a research report on Monday, August 19th. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of GeoVax Labs in a research report on Monday, August 12th. Roth Capital upgraded shares of GeoVax Labs to a “strong-buy” rating in a research report on Tuesday, July 16th. EF Hutton Acquisition Co. I raised shares of GeoVax Labs to a “strong-buy” rating in a research report on Tuesday, July 23rd. Finally, Roth Mkm assumed coverage on GeoVax Labs in a report on Tuesday, July 16th. They issued a “buy” rating and a $20.00 target price on the stock. Three research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $12.67.

Institutional Investors Weigh In On GeoVax Labs

An institutional investor recently bought a new position in GeoVax Labs stock. Armistice Capital LLC acquired a new position in shares of GeoVax Labs, Inc. (NASDAQ:GOVX) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 1,626,516 shares of the company’s stock, valued at approximately $587,000. Armistice Capital LLC owned about 91.38% of GeoVax Labs at the end of the most recent reporting period. Institutional investors and hedge funds own 6.09% of the company’s stock.

GeoVax Labs Stock Performance

NASDAQ:GOVX traded down $0.63 during midday trading on Tuesday, hitting $5.97. 2,858,861 shares of the company traded hands, compared to its average volume of 2,708,310. The firm’s fifty day moving average is $3.17 and its 200-day moving average is $2.33. GeoVax Labs has a 12-month low of $1.09 and a 12-month high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last released its earnings results on Tuesday, August 6th. The company reported ($1.99) EPS for the quarter, beating analysts’ consensus estimates of ($2.57) by $0.58. The business had revenue of $0.30 million for the quarter. During the same quarter last year, the company posted ($3.30) earnings per share. On average, sell-side analysts anticipate that GeoVax Labs will post -7.41 earnings per share for the current year.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.